Utilization and Treatment Costs of Tumor Necrosis Factor Inhibitors After the Introduction of Biosimilar Infliximab in the United States
Year: 2020
Type: article
Source: Arthritis & Rheumatology
DOI: 10.1002/art.41201
Institutions: Brigham and Women's Hospital, Harvard University
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W3000403758